{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:49:58Z","timestamp":1765828198599,"version":"build-2065373602"},"reference-count":97,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gic","doi-asserted-by":"publisher","award":["308488\/2019-9"],"award-info":[{"award-number":["308488\/2019-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Acromegaly is a chronic and systemic disease due to excessive growth hormone and insulin-like growth factor type I caused, in the vast majority of cases, by a GH-secreting pituitary adenoma. About 40% of these tumors have somatic mutations in the stimulatory\u00a0G protein alpha-subunit 1 gene. The pathogenesis of the remaining tumors, however, is still not fully comprehended. Surgery is the first-line therapy for these tumors, and first-generation somatostatin receptor ligands (fg-SRL) are the most prescribed medications in patients who are not cured by surgery. MicroRNAs are small, non-coding RNAs that control the translation of many mRNAs, and are involved in the post-transcriptional regulation of gene expression. Differentially expressed miRNAs can explain differences in the pathogenesis of acromegaly and tumor resistance. In this review, we focus on the most validated miRNAs, which are mainly involved in acromegaly\u2019s tumorigenesis and fg-SRL resistance, as well as in circulating miRNAs in acromegaly.<\/jats:p>","DOI":"10.3390\/ijms23158653","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T23:33:01Z","timestamp":1659569581000},"page":"8653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9514-0986","authenticated-orcid":false,"given":"Daniel G.","family":"Henriques","sequence":"first","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Division, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-901, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa B.","family":"Lamback","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Division, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-901, Brazil"},{"name":"Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Rio de Janeiro 20231-092, Brazil"},{"name":"Neuroendocrinology Division, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Rio de Janeiro 20231-092, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5838-0881","authenticated-orcid":false,"given":"Romulo S.","family":"Dezonne","sequence":"additional","affiliation":[{"name":"Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Rio de Janeiro 20231-092, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1339-3192","authenticated-orcid":false,"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Division, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-901, Brazil"},{"name":"Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Rio de Janeiro 20231-092, Brazil"},{"name":"Neuroendocrinology Division, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Rio de Janeiro 20231-092, Brazil"},{"name":"Endocrinology Division, Hospital Federal de Bonsucesso, Rio de Janeiro 21041-020, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica R.","family":"Gadelha","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Division, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-901, Brazil"},{"name":"Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Rio de Janeiro 20231-092, Brazil"},{"name":"Neuroendocrinology Division, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Rio de Janeiro 20231-092, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/BF03344942","article-title":"Acromegaly: An epidemiological study","volume":"16","author":"Etxabe","year":"1993","journal-title":"J. Endocrinol. Investig."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.20945\/2359-3997000000193","article-title":"Determinants of morbidities and mortality in acromegaly","volume":"63","author":"Kasuki","year":"2019","journal-title":"Arch. Endocrinol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2020.05.007","article-title":"Acromegaly: Update on Management and Long-Term Morbidities","volume":"49","author":"Kasuki","year":"2020","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: An update","volume":"94","author":"Melmed","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","article-title":"Predictors of surgical outcome and early criteria of remission in acromegaly","volume":"60","author":"Antunes","year":"2018","journal-title":"Endocrine"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"E1730","DOI":"10.1210\/jc.2013-2145","article-title":"Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide","volume":"98","author":"Heck","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","article-title":"Somatostatin receptor ligands in the treatment of acromegaly","volume":"20","author":"Gadelha","year":"2017","journal-title":"Pituitary"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine Learning-based Prediction Model for Treatment of Acromegaly with First-generation Somatostatin Receptor Ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","article-title":"Pasireotide for the treatment of acromegaly","volume":"17","author":"Wildemberg","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The Future of Somatostatin Receptor Ligands in Acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_16","first-page":"84","article-title":"Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: The importance of dose adjustment to achieve long-term biochemical control","volume":"16","author":"Shimon","year":"2017","journal-title":"Hormones"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s11102-015-0662-5","article-title":"Impact of gsp mutations in somatotroph pituitary adenomas on growth hormone response to somatostatin analogs: A meta-analysis","volume":"18","author":"Efstathiadou","year":"2015","journal-title":"Pituitary"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wildemberg, L.E., Henriques, D., Elias, P.C.L., Lima, C.H.A., Musolino, N.R.C., Camacho, A.H.S., Faria, O., Nazato, D., Abucham, J., and Vilar, L. (2021). Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. Cancers, 13.","DOI":"10.3390\/cancers13194857"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1136\/jmedgenet-2017-104957","article-title":"Risk category system to identify pituitary adenoma patients with","volume":"55","author":"Caimari","year":"2018","journal-title":"J. Med. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1530\/EC-17-0237","article-title":"Mutations in Brazilian patients with sporadic pituitary adenomas: A single-center evaluation","volume":"6","author":"Araujo","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"E663","DOI":"10.1210\/jc.2011-2291","article-title":"Germline AIP mutations in apparently sporadic pituitary adenomas: Prevalence in a prospective single-center cohort of 443 patients","volume":"97","author":"Cazabat","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-12-0763","article-title":"Genetic analysis in young patients with sporadic pituitary macroadenomas: Besides AIP don\u2019t forget MEN1 genetic analysis","volume":"168","author":"Cuny","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000345673","article-title":"Genetics of pituitary adenomas","volume":"41","author":"Gadelha","year":"2013","journal-title":"Front. Horm. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0092-8674(93)90529-Y","article-title":"The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14","volume":"75","author":"Lee","year":"1993","journal-title":"Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-6524-3_1","article-title":"MiRNA Biogenesis and Regulation of Diseases: An Overview","volume":"1509","author":"Vishnoi","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan MicroRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1093\/emboj\/cdf476","article-title":"MicroRNA maturation: Stepwise processing and subcellular localization","volume":"21","author":"Lee","year":"2002","journal-title":"EMBO J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/BF03346759","article-title":"MicroRNAs: Suggested role in pituitary adenoma pathogenesis","volume":"36","author":"Gadelha","year":"2013","journal-title":"J. Endocrinol. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1261\/rna.068692.118","article-title":"Post-transcriptional control of miRNA biogenesis","volume":"25","author":"Michlewski","year":"2019","journal-title":"RNA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"E1881","DOI":"10.1073\/pnas.1602532113","article-title":"Re-evaluation of the roles of DROSHA, Export in 5, and DICER in microRNA biogenesis","volume":"113","author":"Kim","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cell.2007.06.028","article-title":"The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila","volume":"130","author":"Okamura","year":"2007","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.7150\/ijbs.47203","article-title":"miRNA-based biomarkers, therapies, and resistance in Cancer","volume":"16","author":"He","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Correia de Sousa, M., Gjorgjieva, M., Dolicka, D., Sobolewski, C., and Foti, M. (2019). Deciphering miRNAs\u2019 Action through miRNA Editing. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246249"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature10888","article-title":"The microcosmos of cancer","volume":"482","author":"Lujambio","year":"2012","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nrclinonc.2014.5","article-title":"Clinical relevance of circulating cell-free microRNAs in cancer","volume":"11","author":"Schwarzenbach","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.chest.2017.06.026","article-title":"Extracellular Vesicles in Lung Disease","volume":"153","author":"Kubo","year":"2018","journal-title":"Chest"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jalz.2019.06.4952","article-title":"Differential expression of microRNAs in Alzheimer\u2019s disease brain, blood, and cerebrospinal fluid","volume":"15","author":"Takousis","year":"2019","journal-title":"Alzheimers Dement."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-4939-7172-5_23","article-title":"Urine Exosome Isolation and Characterization","volume":"1641","author":"Street","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1373\/clinchem.2003.028506","article-title":"Characterization of amplifiable, circulating RNA in plasma and its potential as a tool for cancer diagnostics","volume":"50","author":"Raja","year":"2004","journal-title":"Clin. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105125","DOI":"10.1016\/j.archoralbio.2021.105125","article-title":"Analysis of periodontitis-associated miRNAs in gingival tissue, gingival crevicular fluid, saliva and blood plasma","volume":"126","author":"Rovas","year":"2021","journal-title":"Arch. Oral Biol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/ncb2210","article-title":"MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins","volume":"13","author":"Vickers","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/ncb1596","article-title":"Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells","volume":"9","author":"Valadi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40618-015-0316-5","article-title":"Circulating miRNAs as biomarkers for endocrine disorders","volume":"39","author":"Butz","year":"2016","journal-title":"J. Endocrinol. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41580-021-00354-w","article-title":"MicroRNA-mediated regulation of glucose and lipid metabolism","volume":"22","author":"Agbu","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1373\/clinchem.2007.097972","article-title":"Detection and characterization of placental microRNAs in maternal plasma","volume":"54","author":"Chim","year":"2008","journal-title":"Clin. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1101\/gr.198788.115","article-title":"Degradation dynamics of microRNAs revealed by a novel pulse-chase approach","volume":"26","author":"Marzi","year":"2016","journal-title":"Genome Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"368975","DOI":"10.1155\/2013\/368975","article-title":"Genome-wide analysis of human microRNA stability","volume":"2013","author":"Li","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cr.2008.282","article-title":"Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases","volume":"18","author":"Chen","year":"2008","journal-title":"Cell Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00251-020-01201-6","article-title":"A systematic review of microRNAs as potential biomarkers for diagnosis and prognosis of gastric cancer","volume":"73","author":"Ahadi","year":"2021","journal-title":"Immunogenetics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.drudis.2016.10.014","article-title":"miRNA nanotherapeutics for cancer","volume":"22","author":"Ganju","year":"2017","journal-title":"Drug Discov. Today"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12020-017-1390-6","article-title":"Increased miR-338-3p expression correlates with invasiveness of GH-producing pituitary adenomas","volume":"58","author":"Lee","year":"2017","journal-title":"Endocrine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1746-1596-5-79","article-title":"Differential expression of microRNAs in GH-secreting pituitary adenomas","volume":"5","author":"Mao","year":"2010","journal-title":"Diagn. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/onc.2012.190","article-title":"Functional screen analysis reveals miR-26b and miR-128 as central regulators of pituitary somatomammotrophic tumor growth through activation of the PTEN-AKT pathway","volume":"32","author":"Palumbo","year":"2013","journal-title":"Oncogene"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E1128","DOI":"10.1210\/jc.2011-3482","article-title":"Altered microRNA expression profile in human pituitary GH adenomas: Down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1","volume":"97","author":"Palmieri","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jcp.20282","article-title":"miR-15a and miR-16-1 down-regulation in pituitary adenomas","volume":"204","author":"Bottoni","year":"2005","journal-title":"J. Cell. Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"R331","DOI":"10.1530\/ERC-14-0188","article-title":"The PI3K\/AKT\/mTOR pathway in the pathophysiology and treatment of pituitary adenomas","volume":"21","author":"Monsalves","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1677\/ERC-08-0012","article-title":"Pituitary tumor-transforming gene in endocrine and other neoplasms: A review and update","volume":"15","author":"Salehi","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8516858","DOI":"10.1155\/2019\/8516858","article-title":"Identification of Serum miRNA-423-5p Expression Signature in Somatotroph Adenomas","volume":"2019","author":"Zhao","year":"2019","journal-title":"Int. J. Endocrinol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"18317","DOI":"10.1002\/jcp.28465","article-title":"Wnt pathway targeting reduces triple-negative breast cancer aggressiveness through miRNA regulation in vitro and in vivo","volume":"234","author":"Hosseini","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_63","first-page":"8411","article-title":"MicroRNA-381 inhibits lung adenocarcinoma cell biological progression by directly targeting LMO3 through regulation of the PI3K\/Akt signaling pathway and epithelial-to-mesenchymal transition","volume":"23","author":"Xuan","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"535665","DOI":"10.3389\/fonc.2020.535665","article-title":"MicroRNA-381-A Key Transcriptional Regulator: Its Biological Function and Clinical Application Prospects in Cancer","volume":"10","author":"Zeng","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.gendis.2014.10.004","article-title":"Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance","volume":"2","author":"Denduluri","year":"2015","journal-title":"Genes Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/modpathol.2008.202","article-title":"Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas","volume":"22","author":"Qian","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1055\/a-0585-7410","article-title":"MicroRNAs and Target Genes in Pituitary Adenomas","volume":"50","author":"Feng","year":"2018","journal-title":"Horm. Metab. Res."},{"key":"ref_68","first-page":"5833","article-title":"The biochemical and clinical implications of phosphatase and tensin homolog deleted on chromosome ten in different cancers","volume":"11","author":"Wang","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_69","first-page":"15330338211070689","article-title":"Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma","volume":"21","author":"Wang","year":"2022","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3389\/fphar.2020.00904","article-title":"Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies","volume":"11","author":"Tanabe","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT pathway in cancer: The framework of malignant behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.23736\/S0031-0808.17.03386-9","article-title":"Tumor suppressor role of miR-503","volume":"60","author":"Gupta","year":"2018","journal-title":"Panminerva Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"9957","DOI":"10.2147\/OTT.S257951","article-title":"miR-525-5p Modulates Proliferation and Epithelial-Mesenchymal Transition of Glioma by Targeting Stat-1","volume":"13","author":"Xie","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1007\/s10620-019-05916-9","article-title":"MiR-525-5p Repressed Metastasis and Anoikis Resistance in Cervical Cancer via Blocking UBE2C\/ZEB1\/2 Signal Axis","volume":"65","author":"Chen","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1055\/s-0028-1096125","article-title":"MicroRNAs and possible role in pituitary adenoma","volume":"26","author":"Zatelli","year":"2008","journal-title":"Semin. Reprod. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1093\/carcin\/bgs261","article-title":"The putative tumor suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in glioma","volume":"33","author":"Chen","year":"2012","journal-title":"Carcinogenesis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF03401377","article-title":"The role of Notch and Hedgehog signaling pathways in pituitary development and pathogenesis of pituitary adenomas","volume":"14","author":"Yavropoulou","year":"2015","journal-title":"Hormones"},{"key":"ref_78","first-page":"789","article-title":"MiR-524-5p Suppresses Migration, Invasion, and EMT Progression in Breast Cancer Cells through Targeting","volume":"35","author":"Jin","year":"2020","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"G827","DOI":"10.1152\/ajpgi.00369.2019","article-title":"miR-524-5p inhibits angiogenesis through targeting WNK1 in colon cancer cells","volume":"318","author":"Li","year":"2020","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"111198","DOI":"10.1016\/j.biopha.2020.111198","article-title":"An update on the role of miR-124 in the pathogenesis of human disorders","volume":"135","author":"Shoorei","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1007\/s13277-014-2143-2","article-title":"Pituitary tumor-transforming gene 1 (PTTG1) is overexpressed in oral squamous cell carcinoma (OSCC) and promotes migration, invasion and epithelial-mesenchymal transition (EMT) in SCC15 cells","volume":"35","author":"Zhang","year":"2014","journal-title":"Tumour Biol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s13277-014-2609-2","article-title":"Pttg1 inhibits TGF\u03b2 signaling in breast cancer cells to promote their growth","volume":"36","author":"Zhang","year":"2015","journal-title":"Tumour Biol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1210\/jcem.84.2.5432","article-title":"Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas","volume":"84","author":"Zhang","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"E708","DOI":"10.1152\/ajpendo.00546.2011","article-title":"MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro","volume":"303","author":"Trivellin","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"R101","DOI":"10.1530\/JOE-17-0254","article-title":"AIP and the somatostatin system in pituitary tumours","volume":"235","author":"Korbonits","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Denes, J., Kasuki, L., Trivellin, G., Colli, L.M., Takiya, C.M., Stiles, C.E., Barry, S., de Castro, M., Gadelha, M.R., and Korbonits, M. (2015). Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117107"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/ijc.33268","article-title":"miR-34a is upregulated in AIP-mutated somatotropinomas and promotes octreotide resistance","volume":"147","author":"Bogner","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_88","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J. Endocrinol. Investig."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s40618-015-0306-7","article-title":"Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185","volume":"38","author":"Fan","year":"2015","journal-title":"J. Endocrinol. Investig."},{"key":"ref_90","first-page":"2160","article-title":"A Significant Upregulation of miR-886-5p in High Grade and Invasive Bladder Tumors","volume":"12","author":"Khoshnevisan","year":"2015","journal-title":"Urol. J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2010.09.009","article-title":"MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells","volume":"120","author":"Li","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000499620","article-title":"The Biological Function and Clinical Significance of miR-886-5p in Multiple Myeloma","volume":"142","author":"Xiang","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"Management of Endocrine Disease: Personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.3906\/sag-2010-245","article-title":"Circulating miR-29c-3p is downregulated in patients with acromegaly","volume":"51","author":"Korkmaz","year":"2021","journal-title":"Turk. J. Med. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/clinem\/dgab695","article-title":"Circulating Plasma MicroRNA in Patients with Active Acromegaly","volume":"107","author":"Lutsenko","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.3892\/ol.2020.11845","article-title":"miR-452-5p and miR-215-5p expression levels in colorectal cancer tissues and their relationship with clinicopathological features","volume":"20","author":"Yan","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"924952","DOI":"10.3389\/fendo.2022.924952","article-title":"Acromegaly and Colorectal Neoplasm: An Update","volume":"13","author":"Kasuki","year":"2022","journal-title":"Front. Endocrinol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8653\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:03:51Z","timestamp":1760141031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":97,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23158653"],"URL":"https:\/\/doi.org\/10.3390\/ijms23158653","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}